Grifols, S.A. (0RDV.L)
| Previous close | 10.31 |
| Open | 10.31 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 10.14 - 10.18 |
| 52-week range | 5.86 - 12.04 |
| Volume | |
| Avg. volume | 53,311 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Three Stocks Estimated To Be Trading With Intrinsic Discounts Between 35.9% And 49.7%
As global markets exhibit mixed signals with the S&P 500 reaching record highs amid cooling labor markets and easing inflation pressures, investors are navigating a complex landscape. In such an environment, identifying stocks that are trading below their intrinsic value could present opportunities for discerning investors looking to potentially enhance their portfolios.
GlobeNewswireGrifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols’ strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other prote
Simply Wall St.Grifols Leads Three Stocks That May Be Priced Below Their Estimated True Value
As global markets exhibit mixed signals with modest gains in the U.S. and challenges in sectors like Chinese real estate, investors are keenly watching for opportunities that might be undervalued. In this environment, identifying stocks such as Grifols that potentially trade below their intrinsic value could offer attractive entry points amidst current market conditions.
